Abstract: A composition which provides a comprehensive solution for curbing, moderating and/or reducing the symptoms and cravings of opioid withdrawal syndrome. The composition is provided in the form of a capsule, pill, liquid, powder for mixing, or patch. In accordance with embodiments of the invention a composition for treating opioid withdrawal syndrome is provided. The composition includes (i) a therapeutically effective amount of a functional blend comprising a mixture of cannabidiol, cannabigerol, gamma aminobutyric acid, Inositol, and Vitamin B-12; (ii) a therapeutically effective amount of a hydration blend comprising a mixture of calcium, magnesium, potassium citrate, and L-glutamine; (iii) a therapeutically effective amount of an anti-inflammatory blend comprising a mixture of turmeric, green tea, and passion fruit; and (iv) a therapeutically effective amount of a neurotransmitter blend comprising 5-hydroxy-L-Tryptophan, N-acetyl L-Tyrosine, and L-Phenylalanine.

Abstract: The present invention relates to a novel cannabinoid oral pharmaceutical dosage form, based on a Type IV or Type IV-like formulation, as classified using the Lipid Formulation Classification System. The formulation is contained in a container. By Type IV-like, it is meant that the formulation comprises no oil, for example no triglycerides or mixed glycerides.

Abstract: Disclosed herein are compositions and methods for delivering cannabidiol to subject in need of hypertension treatment. The disclosed compositions are orally delivered. Further disclosed are kits comprising the disclosed compositions as part of a method of delivering the cannabidiol-containing compositions.

Abstract: Provided herein are compositions for inducing anesthesia in a subject, where the compositions include at least one compound that is either a terpenoid or a salicylate. The provided compositions are particularly useful for applications where the subject is a livestock animal used for meat or milk production, as the anesthetic agents have no toxic effects on food byproducts. The compositions provide further advantages for applications where the subject is a human undergoing a medical procedure. Also provided are methods for using the disclosed compositions and compounds.

Abstract: The present invention includes a method for selecting a subject for a targeted treatment for Parkinson's Disease, the method comprising: obtaining or having obtained a sample from the subject; measuring in the blood or serum sample the expression level of one or more first biomarkers; comparing the level of expression of the one or more first biomarkers from the subject's sample with the expression level of a corresponding one or more first biomarkers from a statistical sample representative of biomarkers in a normal subject; and if the subject is found to have a statistically different expression level of the one or more biomarkers when compared to the expression level of the corresponding one or more biomarkers from the statistical sample, treating the subject with a monoamine oxidase inhibitor, an antioxidant, or both.

Abstract: Disclosed herein is the use of purified 2-S rimantadine or purified 2-R rimantadine or a pharmaceutically acceptable thereof to treat cancers and precancer lesions, including cancers and precancer lesions associated with papilloma virus in subjects in need of treatment.

Abstract: The present disclosure relates to a method for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by orally administering an effective amount of mirdametinib to the patient, where an amount of mirdametinib is administered on the first day of treatment to provide (i) an AUC0-tau less than 400 ng·h/mL, (ii) a Cmax no more than 40 ng/ml, or (iii) both.

Abstract: A tablet includes an active material and a base material that carnauba wax and an oil.

Abstract: Disclosed herein is a method for treating a solid tumor in a subject that involves assaying a sample from the subject for expression of two or more Histone deacetylases (HDACs); determining a response score from the expression of the two or more HDACs, wherein the response score predicts whether the subject will respond to combination immunotherapy and HDAC inhibitor therapy; and administering to the subject a therapeutically effective amount of a combination of immunotherapy and an HDAC inhibitor.

Abstract: A tablet includes an active material and a base material comprising carnauba wax and an oil. A tablet formulation can contain an active pharmaceutical ingredient and a base material that includes carnauba wax. The carnauba wax constitutes more than 50% of the base material.

Abstract: Disclosed herein are methods and compositions for treatment and prevention of neuropathic pain conditions. Aspects of the present disclosure are directed to methods for treatment of neuropathic pain conditions using STAT3 inhibitors. Certain aspects pertain to TTI-101 and methods for use in treatment of chemotherapy-induced peripheral neuropathy, mechanical nerve injury, and other neuropathic pain conditions. Also disclosed are methods for treatment of chemotherapy-induced peripheral neuropathy comprising administering TTI-101 and one or more chemotherapeutic agents to a subject with cancer.

Abstract: The present invention relates a method for the use of a product with propyl propane thiosulfonate (PTSO), whose purpose is the treatment and/or prophylaxis of malignant neoplasms such as solid cancers and myeloproliferative syndromes in humans. In a preferred embodiment, the method includes the selection of the PTSO compound which general formula is R-SOa-S-R, where “R” represents the n-propyl group (—CH2—CH2—CH3) and “a” is 2.

Abstract: In various implementations, beta-hydroxybutyrate, related compounds, and/or one or more other compounds may be administered to an individual to cause weight loss, weight maintenance, elevate blood ketone levels, maintain blood ketone levels, reduce blood glucose levels, maintain blood glucose levels, improve energy, focus, mood, cognitive function, or aide with neurological or inflammatory disorders and/or combinations thereof.

Abstract: The invention provides a process for preparing an aqueous pharmaceutical solution of calcium gluconate. The process comprises the steps of: (i) mixing calcium gluconate, calcium saccharate and water at a mixing temperature of 60-100° C. to form a bulk solution; (ii) filling portions of the bulk solution into containers at a filling temperature of 60-100° C.; and (iii) sealing the containers with a closure. The invention also provides a batch of containers obtainable by this process.

Abstract: Provided herein are rumen-protected compositions. The compositions include coated rumen-protected compositions which comprise a coating and a bioactive core comprising a physiologically active ingredient. The coating includes a chitosan organic salt, an emulsifier, and a fatty acid source. Further provided are rumen-protected pellet compositions, which may optionally comprise a coating. The pellet compositions include a bioactive core comprising a physiologically active ingredient and a chitosan organic salt. Further provided are methods of making the compositions and methods of delivering methionine to an animal.

Abstract: A composition containing lysine for the treatment of poison ivy and/or poison oak, a composition containing lysine for the prevention of poison ivy and/or poison oak, processes, and methods of use are presented. Thus, a composition and treatment including Lysine for the treatment and/or prevention of urushiol-induced contact dermatitis (otherwise known as poison ivy and/or poison oak) is presented. The disclosure provides a composition containing lysine for the treatment and/or prevention of effects caused by exposure to urushiol and/or a liquid composed of plant sap. More specifically, the present disclosure relates to a supplement which can be taken daily and/or as a treatment for poison ivy and/or other allergens and/or allergic reactions.

Abstract: Liquid food product suitable to manage the ketogenic diet, which comprises at least lipids, carbohydrates, fibers, proteins and water.

Abstract: Provided herein are methods of reducing the risk of myocardial infarction or coronary revascularization in an adult with established cardiovascular disease or two or more risk factors for cardiovascular disease. Also provided herein are methods of reducing low-density lipoprotein cholesterol in an adult with primary hyperlipidemia. The methods described herein generally comprise administering to the adult an effective amount of bempedoic acid.

Abstract: Provided herein are methods of reducing the risk of myocardial infarction or coronary revascularization in an adult with established cardiovascular disease or two or more risk factors for cardiovascular disease. Also provided herein are methods of reducing low-density lipoprotein cholesterol in an adult with primary hyperlipidemia. The methods described herein generally comprise administering to the adult an effective amount of bempedoic acid.

Abstract: There is provided a vegetable-based lipid composition comprising very high levels of DHA, together with at least one other long-chain polyunsaturated fatty acid (typically as fatty acid esters). The composition typically contains low levels of EPA and palmitic acid. The composition is obtainable from a single source by conventional processing methods, and has improved stability properties.

Abstract: Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

Abstract: The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to a composition comprising a specific combination of lipids and optionally one or more additives, and a method of preparing said composition. Furthermore, the present invention relates to the composition of the present invention for use as a medicament, for use in the treatment of dry eye disease and/or Meibomian gland dysfunction, and for use in alleviation of eye discomfort. Moreover, the present invention relates to a method of treating dry eye disease and/or Meibomian gland dysfunction, or alleviating eye discomfort. In addition, the present invention relates to a non-therapeutic or therapeutic method of retarding evaporation of water and use of the composition of the present invention for preventing evaporation of water.

Abstract: A controlled release pharmaceutical composition for eye injection for ophthalmic care. The composition comprises at least one active pharmaceutical ingredient and at least one biocompatible polymer and at least one biocompatible solvent. The composition, which is capable of forming an in-situ implant composition, comprises an injectable solution, suspension, emulsion or dispersion. The formulation can be injected through a needle that is suitable in size for an eye injection. The present compositions can be used for treatment of ophthalmic conditions, including glaucoma, dry and wet age-related macular degeneration, diabetic retinopathy, dry eye syndrome, and uveitis.

Abstract: Methods are described for preventing or treating skeletal diseases such as period paralysis by administering to a subject a Kv7 channel opener.

Abstract: Tasimelteon improves sleep in individuals experiencing an advance in established bedtime.

Abstract: The invention relates generally to improving sleep, post-sleep performance, or both and, more particularly, to so improving without inducing post-sleep effects that would impair an individual's ability to operate machinery or a motor vehicle.

Abstract: The present invention relates to the compound monensin as a potent agent or drug for dampening the harmful activities of mast cells and eosinophils, and use of the same in the alleviation, treatment and/or prevention of mast cell- or eosinophil-dependent pathologies, such as inflammatory diseases.

Abstract: This disclosure provides cannabinoid compositions with improved shelf-life stability, methods of use thereof, and methods of preparation thereof.

Abstract: The present invention relates to a composition that can suppress angiogenesis and overcome the resistance of cancer cells occurring in a low-carbohydrate state, and thus can be used for angiogenesis suppression and adjuvant anticancer treatment.

Abstract: Liposomal polyphenol compositions comprised of lipophilic glycoside free flavonoids and cannabinoids, each separately and optimally encapsulated within membrane lipid bilayers of mostly spherical vesicles, their methods of preparation and their potential use when dispersed into pharmaceutically acceptable bases for treating and preventing various skin disorders.

Abstract: A method for treating Zika virus infection with a composition containing quercetin or isoquercetin, together with one or more of vitamin B3, vitamin C, and a folate compound is described. Methods of preventing microcephaly and treating and preventing infections of other Flavivridae viruses are also described.

Abstract: The present invention relates to retromer complex activators and compositions for use in the treatment and/or prevention of neurological and psychiatric disorders characterized by Kidins220 dysfunction in a subject. These disorders may be further characterized by ventriculomegaly and/or excitotoxicity. It also relates to methods for screening a retromer complex activator for use in the treatment and/or prevention of said disorders in a subject.

Abstract: The present disclosure discloses a composition comprising (2?Z, 3?E)-6-Bromoindirubin-3?-oxime or its derivative for use in treatment of neurodevelopmental and of neurodegenerative disorders. The disclosure further relates to a method for correcting the behavioural deficits in a subject with neurodevelopmental and neurodegenerative disorders comprising administering the subject with a therapeutically effective amount of (2?Z, 3?E)-6-Bromoindirubin-3?-oxime or its derivative.

Abstract: An edaravone suspension for human oral administration includes edaravone particles, a dispersant, and water.

Abstract: A method of treating cancer-related cognitive decline (CRCD) in a patient, in which the method comprises administering to the patient an effective amount of an inhibitor of receptor for advanced glycation endproducts (RAGE). The inhibitor of RAGE may be administered as a single dose or as multiple doses before the administration of the cancer therapy, during the administration of the cancer therapy, after the administration of the cancer therapy, or a combination thereof. Administration of the inhibitor of RAGE may improve attention, processing speed, executive functioning, learning, memory, or a combination thereof, of the patient as compared to patients who are not administered the inhibitor of RAGE.

Abstract: The invention relates to compounds capable of inducing autophagy and metabolic reprogramming and to the use thereof as cardioprotectors, in particular in the context of anticancer therapy.

Abstract: The present disclosure provides methods, uses, and pharmaceutical compositions comprising and azole derivative (e.g., sulconazole) in the treatment or prevention of fibrotic disease or disorder or fibrosis, including Crohn's disease.

Abstract: The present invention relates to a composition of disease-modifying antirheumatic drugs (DMARDs) for treatment of auto-immune diseases. More particularly, the invention relates to the microemulsion based emulgel composition of DMARD-leflunomide or its derivatives for treatment of auto-immune diseases such as rheumatoid arthritis, atopic dermatitis, psoriasis and skin cancer such as melanoma, squamous cell carcinoma. The invention also discloses a method for preparation of microemulsion based emulgel composition with improved physicochemical, pharmacokinetic properties of leflunomide to be used in pharmaceutical compositions. This invention discloses the delivery of leflunomide across human skin for the treatment of autoimmune and oncological conditions. The unique delivery of leflunomide in the form of microemulsion based emulgel composition is disclosed.

Abstract: Provided herein is vafidemstat for use in a method for treating autism spectrum disorder.

Abstract: Provided herein are pharmaceutical compositions including a URAT1 inhibitor and methods of use thereof. The pharmaceutical compositions can include dotinurad, a xanthine oxidase inhibitor, such as allopurinol and/or a sodium-glucose cotransporter-2 inhibitor. The pharmaceutical compositions described herein can be used for the treatment of diseases and conditions related to uric acid, including chronic kidney disease.

Abstract: In some embodiments of the present disclosure, a sustained release osmotic-controlled pharmaceutical composition is provided, including: a core and a semi-permeable membrane coated on the core. The core includes a drug compartment, in which the drug compartment includes a first active ingredient, a first polymer and a first osmogen, and the first active ingredient includes lurasidone, a pharmaceutical acceptable salt of the lurasidone or a combination thereof. The semi-permeable membrane includes a membrane body and at least one pore distributed in the membrane body.

Abstract: The current invention relates to a pharmaceutical composition comprising an effective amount of cabazitaxel, or a CYP3A inhibitor, for use in a combination treatment in the treatment of cancer in a patient. The combination treatment comprises administering the pharmaceutical composition and the CYP3A inhibitor, and the dose of the CYP3A inhibitor is equivalent to 40 to 120 mg ritonavir. The current invention also relates to method and kit for the combination treatment thereof.

Abstract: The present disclosure provides tetrahydro-1H-pyrido[3,4-b]indole compounds or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, stereoisomer, tautomer, rotamer, N-oxide and/or substituted derivative or, optionally in a pharmaceutical composition, for the modulation of disorders mediated by estrogen, or other disorders as more fully described herein.

Abstract: Accurate methods for detecting cancer and for determining the prognosis of cancer, including breast cancer, are described herein, using biomarkers referred to herein as the ET-29, HDAC1, HDAC7, and ZNF92. Upregulation of HDAC1, HDAC7, and ZNF92 and optionally one or more genes in ET-29 biomarkers predicts sensitivity to a three-drug combination that includes histone deacetylase inhibitor(s) (HDAC), heat shock protein 90 (HSP90) inhibitor(s), and helminth(s).

Abstract: A vertically-integrated cannabis-related product production method is described, the method comprises, producing a distilled cannabinoid and/or a crystallized cannabinoid from cannabis plants, comprising: in a farming system, growing the cannabis plants, the cannabis plants comprise a cannabinoid; in an extraction system, extracting the cannabinoid from the cannabis plants; in a purification system, purifying the cannabinoid to produce a purified cannabinoid; and in a distillation and/or a crystallization system, distilling and/or crystallizing the purified cannabinoid to produce the distilled cannabinoid and/or the crystallized cannabinoid. Various ways to purify, distill, and process the cannabinoids are described. In insect pest management system may be integrated with the farming system to grow the cannabis plants in the presence of predatory mites which feed on insects and/or spider mites.

Abstract: Methods are provided for treating allergies, asthma, or mast cell activation syndrome with a tryptase inhibitor. In particular, methods of treating allergies, asthma, or mast cell activation syndrome with the tryptase inhibitor, Avoralstat, are disclosed.

Abstract: Compositions, methods, and uses are contemplated in which a betalain-containing preparation is administered to a mammal to enhance athletic performance. Most preferably, the preparations are substantially nitrate free and acutely and transiently increase hematocrit, erythropoietin, adrenalin, and beta endorphin, while reducing serum lactate, serum lactate dehydrogenase, heart rate and a rate of perceived exertion.

Abstract: A method of performing a microfracture procedure includes creating fractures in subchondral bone and administering a Wnt pathway inhibitor.

Abstract: This invention relates to a topical anaesthetic composition having improved adrenaline stability, its method of manufacture, and its use as a topical anaesthetic, particularly in medical applications such as animal husbandry procedures.

Abstract: The present invention relates to a pharmaceutical mixture comprising amorphous pitolisant free base or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient. The present invention also related to an oral dosage form containing the pharmaceutical mixture and a method for treating narcolepsy with or without cataplexy.